. "1"^^ . . "RIV/00216224:14110/07:00022371" . "1"^^ . "4" . . "CZ - \u010Cesk\u00E1 republika" . "RIV/00216224:14110/07:00022371!RIV10-MSM-14110___" . "8"^^ . "\u010Ce\u0161kov\u00E1, Eva" . "Pharmacoresistant Schizophrenia"@en . . "pharmacoresistant schizophrenia; antipsychotics; high doses; clozapine; polypharmacotherapy; combination of antipsychotic; augmentation of antipsychotics"@en . "Farmakorezistentn\u00ED schizofrenie"@cs . "Farmakorezistentn\u00ED schizofrenie" . . . . "103" . . . "Pharmacoresistant Schizophrenia"@en . "Sd\u011Blen\u00ED se zab\u00FDv\u00E1 definic\u00ED a stanoven\u00EDm farmakorezistentn\u00ED schizofrenie a mo\u017Enostmi jej\u00ED l\u00E9\u010Dby. V posledn\u00ED dob\u011B se p\u0159i hodnocen\u00ED farmakorezistence soust\u0159e\u010Fujeme hlavn\u011B na p\u0159etrv\u00E1vaj\u00EDc\u00ED p\u0159\u00EDznaky, proto\u017Ee m\u00E1me k dispozici l\u00E9\u010Debn\u00E9 p\u0159\u00EDstupy, kter\u00E9 preferen\u010Dn\u011B ovliv\u0148uj\u00ED n\u011Bkter\u00E9 p\u0159\u00EDznaky (pozitivn\u00ED, negativn\u00ED, kognitivn\u00ED deficit, afektivn\u00ED). Z l\u00E9\u010Debn\u00FDch postup\u016F je nejprve v\u011Bnov\u00E1na pozornost u\u017Eit\u00ED vysok\u00FDch d\u00E1vek, tj. d\u00E1vek vy\u0161\u0161\u00EDch ne\u017E maxim\u00E1ln\u00EDch ofici\u00E1ln\u011B uveden\u00FDch. Dal\u0161\u00ED mo\u017Enost\u00ED je zm\u011Bna st\u00E1vaj\u00EDc\u00ED l\u00E9\u010Dby na klozapin a polyfarmakoterapie. Klozapin je v t\u00E9to indikaci st\u00E1le pova\u017Eov\u00E1n za zlat\u00FD standard. Polyfarmakoterapie, hlavn\u011B kombinace antipsychotik i augmentace antipsychotik l\u00E1tkami, kter\u00E9 nejsou prim\u00E1rn\u011B ur\u010Deny k l\u00E9\u010Db\u011B psych\u00F3z, je velmi \u010Dast\u00E1. Z dostupn\u00FDch dat vypl\u00FDv\u00E1, \u017Ee u stabilizovan\u00FDch nemocn\u00FDch se schizofrenn\u00ED poruchou je \u010Dasto polyfarmakoterapie nadbyte\u010Dn\u00E1. M\u011Bla by b\u00FDt proto zva\u017Eov\u00E1na velmi pe\u010Dliv\u011B a individu\u00E1ln\u011B s ohledem na p\u0159etrv\u00E1vaj\u00EDc\u00ED symptomatologii."@cs . "Z(MSM0021622404)" . "Farmakorezistentn\u00ED schizofrenie" . . "\u010Cesk\u00E1 a slovensk\u00E1 psychiatrie" . . . . "421679" . . "0069-2336" . "14110" . . "Farmakorezistentn\u00ED schizofrenie"@cs . "Sd\u011Blen\u00ED se zab\u00FDv\u00E1 definic\u00ED a stanoven\u00EDm farmakorezistentn\u00ED schizofrenie a mo\u017Enostmi jej\u00ED l\u00E9\u010Dby. V posledn\u00ED dob\u011B se p\u0159i hodnocen\u00ED farmakorezistence soust\u0159e\u010Fujeme hlavn\u011B na p\u0159etrv\u00E1vaj\u00EDc\u00ED p\u0159\u00EDznaky, proto\u017Ee m\u00E1me k dispozici l\u00E9\u010Debn\u00E9 p\u0159\u00EDstupy, kter\u00E9 preferen\u010Dn\u011B ovliv\u0148uj\u00ED n\u011Bkter\u00E9 p\u0159\u00EDznaky (pozitivn\u00ED, negativn\u00ED, kognitivn\u00ED deficit, afektivn\u00ED). Z l\u00E9\u010Debn\u00FDch postup\u016F je nejprve v\u011Bnov\u00E1na pozornost u\u017Eit\u00ED vysok\u00FDch d\u00E1vek, tj. d\u00E1vek vy\u0161\u0161\u00EDch ne\u017E maxim\u00E1ln\u00EDch ofici\u00E1ln\u011B uveden\u00FDch. Dal\u0161\u00ED mo\u017Enost\u00ED je zm\u011Bna st\u00E1vaj\u00EDc\u00ED l\u00E9\u010Dby na klozapin a polyfarmakoterapie. Klozapin je v t\u00E9to indikaci st\u00E1le pova\u017Eov\u00E1n za zlat\u00FD standard. Polyfarmakoterapie, hlavn\u011B kombinace antipsychotik i augmentace antipsychotik l\u00E1tkami, kter\u00E9 nejsou prim\u00E1rn\u011B ur\u010Deny k l\u00E9\u010Db\u011B psych\u00F3z, je velmi \u010Dast\u00E1. Z dostupn\u00FDch dat vypl\u00FDv\u00E1, \u017Ee u stabilizovan\u00FDch nemocn\u00FDch se schizofrenn\u00ED poruchou je \u010Dasto polyfarmakoterapie nadbyte\u010Dn\u00E1. M\u011Bla by b\u00FDt proto zva\u017Eov\u00E1na velmi pe\u010Dliv\u011B a individu\u00E1ln\u011B s ohledem na p\u0159etrv\u00E1vaj\u00EDc\u00ED symptomatologii." . . . . . "The article deals with definition, measurement and treatment possibilities of pharmacoresistant schizophrenia. Recently, when evaluating pharmacoresistance, we have concentrated especially on persistent symptoms because there are treatment options preferentially influencing some symptoms (positive, negative, affective symptoms and cognitive dysfunction). As for treatment possibilities, attention is first paid to the use of high doses of antipsychotic, i.e. higher doses than officially recommended. Further possibilities include switch to clozapine and polypharmacotherapy. Clozapine is still considered to be a gold standard in this indication. Polypharmacotherapy, especially a combination of antipsychotics and augmentation by drugs primary not intended for treatment of psychosis are very frequent. Based on available data in stabilised schizophrenic patients, it seeems that polypharmacotherapy is abundant in many cases."@en . "[03956F6AAC6D]" .